Pre-Study Visits and Site Activation Metrics in Clinical Trials

Introduction: Linking Pre-Study Visits to Activation Success

Pre-study visits (PSVs), also called site qualification visits (SQVs), are critical checkpoints in the site selection and activation process. These visits validate feasibility data, assess infrastructure, and determine whether a site is truly ready to be activated. In parallel, sponsors and CROs use site activation metrics to measure and benchmark performance during study startup. Together, PSVs and activation metrics provide a structured framework to minimize delays, optimize resource allocation, and ensure regulatory compliance in global clinical trials.

This article explores how PSVs should be conducted, what data should be collected, and how activation metrics can be used to track progress and ensure timely site readiness.

1. Objectives of a Pre-Study Visit

PSVs are designed to confirm whether a site can successfully conduct the trial. Objectives include:

• Validating the PI’s experience and availability
• Confirming site infrastructure (labs, storage, equipment, staff)
• Assessing regulatory and ethics submission capabilities
• Reviewing patient recruitment potential and past performance
• Explaining sponsor expectations and operational workflows

These visits provide the final decision point before moving a site forward to activation.

2. Pre-Study Visit Checklist

PSVs should follow a structured checklist to ensure consistency. A typical PSV checklist includes:

• Investigator CVs and medical licenses reviewed
• Good Clinical Practice (GCP) training certificates validated
• Site staff delegation capabilities assessed
• IMP (Investigational Medicinal Product) storage inspected
• Laboratory certifications and reference ranges verified
• Recruitment strategies and patient pools discussed
• Review of past trial enrollment performance

Documenting outcomes in a PSV report is mandatory for TMF and inspection readiness.

3. PSV Outcomes: Go/No-Go Decisions

Based on PSV findings, sites are categorized as:

• Greenlight: Site qualifies with minimal or no corrective actions
• Conditional Approval: Site qualifies but must complete corrective actions (e.g., equipment calibration, staff training)
• No-Go: Site lacks infrastructure, PI experience, or regulatory readiness

Clear documentation of these decisions supports transparency in site selection.

4. Linking PSVs to Site Activation Timelines

PSVs influence activation speed by identifying bottlenecks early. For example:

• Sites missing GCP training may face training delays
• IMP storage issues may require facility upgrades
• Sites with weak recruitment projections may require additional strategies

Addressing these before activation reduces startup risks.

5. Key Site Activation Metrics

Sponsors track site activation metrics to benchmark performance. Common metrics include:

• Average days from feasibility completion to PSV
• Average days from PSV to site activation
• Percentage of sites activated within planned timelines
• Greenlight-to-first-patient-in (FPI) duration
• Contract cycle time (initiation to execution)

6. Case Study: PSV-Linked Delays

Scenario: In a global oncology trial, 12 sites failed activation due to inadequate IMP storage identified during PSV. Corrective actions added 6–8 weeks to timelines.

Resolution: Sponsor implemented a global PSV checklist requiring photos of storage units, calibration certificates, and backup power systems before site selection.

7. Using Technology to Track PSV and Activation Metrics

Digital platforms enhance PSV and activation efficiency by:

• Integrating PSV reports directly into CTMS
• Providing dashboards of PSV-to-activation timelines
• Automating reminders for pending documents or corrective actions
• Benchmarking activation metrics across countries and CROs

Example: A sponsor using an eFeasibility system cut activation delays by 22% by enabling real-time PSV tracking across 15 countries.

8. Risk-Based Site Activation Planning

Not all sites require the same level of oversight. Sponsors should:

• Classify sites into low-, medium-, and high-risk categories based on PSV findings
• Apply enhanced monitoring to sites with conditional approvals
• Prioritize high-performing sites for early activation
• Maintain backup sites to offset potential no-go sites

Risk-based planning ensures trial continuity despite site-level variability.

9. Best Practices for Sponsors and CROs

• Standardize PSV templates across regions
• Link PSV outcomes to site selection scoring systems
• Use activation metrics to identify recurring bottlenecks
• Integrate PSV findings into TMF for inspection readiness
• Train monitors on consistent PSV documentation practices

Conclusion

Pre-study visits and activation metrics are essential tools for ensuring trial readiness and operational efficiency. By conducting standardized PSVs, documenting site capabilities, and tracking performance through key metrics, sponsors and CROs can shorten startup timelines, reduce activation risk, and optimize resource allocation. In global clinical trials, where variability across regions is inevitable, structured PSV assessments and data-driven activation metrics are critical for ensuring timely first-patient-in and overall trial success.